H generated by limited proteolysis from C5 during activation of the complement system. The peptide is an important mediator of the inflammatory response as shown by in vitro and in vivo studies.'.' In vitro C5a stimulates the contraction of smooth muscle, enhances vascular permeability, promotes leukocyte functions such as chemotaxis, degranulation, and mediator release, or production of superoxide anions.',2 The role of C5a in IL-1 production by monocytes is still controversially discu~sed.~.~ Recently, data have been obtained that demonstrate that recombinant C5a increases the secretion of IL-6 by human monocytes that have been stimulated with lipopolysaccharide (LPS) or IL-L6 In vivo C5a generation results in the accumulation of granulocytes and monocytes at sites of inflammation.' Injection of small doses of C5a into normal human skin leads to a wheal and flare reaction, which is partially caused by histamine release of skin mast cells.'~* Serum carboxypeptidase N, which removes the carboy terminal arginyl residues from anaphylatoxins, completely inactivates C3a and C4a, whereas C5a retains diminished biologic activity.'. ' Specific high-affinity receptors for C5a have been defined on granulocytes and stimulated U937 cells.9 They appear to be different from the receptor for the anaphylatoxins C3a and C4a.',Z,9 The receptor for C5a has recently been cloned from U937 and HL-60 cells and expressed in COS-7 cells. It belongs to the rhodopsin superfamily of receptors and displays high-sequence homologies with the receptors for neurokinin A and formyl peptide."' The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 Flow cytometry has been applied to identify C5a-binding cells in peripheral blood with biologically active C5a-F.1"'3 In addition to myeloid cells, some lymphocytes bound C5a-F in these studies. Moreover, lymphocyte subpopulations were shown to respond to C5a in functional in vitro assay^.'^-'^ In this study we used highly purified human C5a-F to evaluate the expression of CSaR on unstimulated and stimulated peripheral blood leukocytes, on spleen cells, and on low-density bone marrow cells. The data obtained with peripheral blood leukocytes were consistent with the responsiveness of leukocyte populations to C5a in vitro and in vivo.
BINDING OF C5a TO HUMAN LEUKOCYTES
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CD56 MoAb NKHIRD' and CD20 MoAb B1" were from Coulter (Krefeld, Germany). MoAb 63D3 (CD14), MMA (CD15), and OKMl (CDllc) were obtained from ATCC (Rockville, MD). The following MoAbs were kindly donated as indicated: 2F12 (CDlla) (R.E. Schmidt, Hannover, Germany), KiMl (CDllc) (J. Radzun, Kiel, Germany), CLB/Fc G r a d (CD16) (T. Huizinga, Amsterdam, The Netherlands), GZ-4 (anti-IFN-y) (G. Zahn, Dr Karl Thomae GmbH, Biberach, Germany). MoAbs CLB/Fc Granl, 63D3, 2F12, MMA, QM1, and OKMl were purified and labeled with fluorescein as de~cribed.'~ Granulocytes were isolated by density gradient centrifugation on neutrophil isolation medium (NIM; Packard, Frankfurt, Germany). Mononuclear cells from healthy donors were isolated by centrifugation on Lymphoprep (d = 1.077 g/cm3) (Nycomed Pharma, Oslo, Norway). Spleen cells were obtained after splenectomy from polytrauma patients without underlying systemic diseases. Cells were suspended after passing splenic tissue through a steel sieve in Iscove's medium and were separated by density centrifugation on Lymphoprep (d = 1.077 g/cm3). Bone marrow aspirates were obtained from patients who were examined in the Department of Hematology, University Hospital of Gottingen, Germany, for various reasons. Data were only evaluated in this study after exclusion of systemic diseases involving the hematopoietic cell system. The low-density leukocytes were washed twice in Iscove's medium after centrifugation on Lymphoprep (d = 1.077 g/cm3). The myeloid cell lines KG-1, HL-60, U937, and THPl were cultured in RPMI 1640 medium supplemented with 5% fetal calf serum. The natural killer (NK) cell clone NKCl was generated and cultured as described.% For the stimulation of MNL with MNL-CM, IFN-y, or by mixed lymphocyte culture (MLC), 106 MNLs from each of two donors were incubated in Iscove's medium supplemented with transferrin, insulin (Sigma), and bovine serum albumin (GIBCO, Eggendorf, Germany) in hydrophobic cell culture plates (Petriperm, Heraeus, Hanau, Germany). For staining and analysis, nonadherent cells and cells that had been detached with 20 mmol/L EDTA in phosphate-buffered saline (PBS) for 20 minutes on ice were pooled.
The method of RinderknechtZ3 was modified according to van Epps and Chenoweth." Concentrated C5a (300 p,g/mL) in 0.1 mol/L sodium phosphate, pH 7.0, was incubated at room temperature with 1 mg fluorescein-isothiocyanate, adsorbed onto Kieselguhr (Serva, Heidelberg, Germany) at room temperature. C5a-F was separated from unconjugated FITC by gel filtration on a PDlO column (Pharmacia, Freiburg, Germany) in PBS. The extent of fluorescein incorporation into C5a as determined by spectrophotometric analysis was 1.0 mol of fluorescein per mol peptide. In SDS-PAGE (3-20% T) C5a-F migrated slightly slower than C5a.
The release of ATP from guinea pig platelets triggered by C5a-F or C5a was assessed by the oxydation of reduced luciferin in a bioluminescence assay as described." It was similar for C5a-F and for C5a. Also, the extent of the translocation of CR3 to the surface granulocytes was nearly identical when the cells were stimulated with C5a or C5a-F. Concentrations of 0.5 to 1 x 10-'omol/L C5a or C5a-F resulted in a maximal response in this assay, which is described below. CR3 was detected in these tests through the use of the PE-labeled MoAb Leul5.
C5a was quantitated by enzyme-linked immunosorbent assay (ELISA) as described?' Briefly, microtiter plates were coated with the neoepitope-specific MoAb C17/5. C5a reactive with this MoAb was detected by a biotinylated monoclonal anti-CS/CSa antibody (MoAb G25/2) followed by a streptavidinperoxidase conjugate.
Stimulation assay. Freshly drawn blood containing 20 mmol/L EDTA and 1 mmol/L MERGETPA to inhibit the carboypepti-
Cells.
Preparation and biologic characterization of CSa-F.
Quantification of C5a.
dase N was incubated for 30 minutes with 2 X lo-' mol/L human C5a at 37°C unless otherwise indicated. Controls contained only EDTA and MERGETPA. The incubation was stopped by washing the cells twice with ice-cold PBS-gelatin (0.2%), containing 20 mmol/L sodium azide. Erythrocytes were removed by lysis with a buffer according to Gey." Lysis was followed by centrifuging the cell suspension (10 minutes, 30%) through a 2 cm layer of heat-inactivated (60 minutes, 56°C) human plasma.
Flow cytometry was performed with a FACStar Plus flow cytometer (Becton Dickinson, Heidelberg, Germany) equipped with an argon laser. The excitation wave length was 488 nm. Granulocytes, monocytes, and lymphocytes were separately analyzed by setting appropriate gates. The major leukocyte populations could be distinguished in most experiments by their characteristic light scatter. Results were verified through the use of C5a-F in combination with PE-labeled CD14 MoAb LeuM3. In these experiments an optimal separation of the cells was achieved by the correlation of side scatter with red fluorescence. Results are expressed as the specific mean channel of fluorescence (MCF) (MCF of test MoAb -MCF of negative control) or as the stimulation index (SI) according to the following formula:
Flow cytometry and analysis.
where Ts = MCF of test MoAb after C5a stimulation, Ns = MCF of negative control after C5a stimulation, To = MCF of test MoAb without stimulation, and No = MCF of negative control without stimulation.
In initial experiments we excluded systematic errors due to properties of the different fluorochromes FITC and PE (eg, quenching due to lower pH during cell activation). The increase in signals after staining with PE-labeled CDllb MoAb Leu15 or FITC-labeled CDllb MoAb OKMl were similar upon stimulation in vitro or during the course of hemodialysis.
Blood was obtained from patients with end-stage renal disease (ESRD) before, during, and after the course of hemodialysis sessions that used cuprophane membranes. Informed consent was obtained from patients with ESRD before 1 to 3 mL EDTA-blood was taken at five different times during one dialysis session. Blood was taken from the efferent blood lines between the patients' veins and the dialyzers. The blood was kept on ice. Cells were stained with FITC-or PE-conjugated MoAb, usually within 20 minutes. Erythrocytes were lysed after staining before analysis of the leukocytes as described above.
Hemodialysis.
RESULTS
Binding of CSa-F to peripheral blood and spleen cells. CSa-F was added to isolated granulocytes or MNL. In both instances, binding to CSaR-positive cells was saturable at 12.5 ng CSa-F after 60 minutes incubation on ice when lo6 cells were used. As was described the density of C5aR on monocytes varied more than on granulocytes (Fig 1) . Granulocytes bound two to three times more CSa-F than monocytes as calculated by MCF. CSa-F binding to granulocytes could not be down-modulated by preincubation of the cells with 500 mU/mL phospho-inositol specific phospholipase C (PI-PLC) at 37°C for 30 minutes. The same dose of PI-PLC was sufficient to reduce the membrane expression of the PI-linked molecule FcyRIII (CD16) by 50% as detected by a reduction in binding of CD16 MoAb CLB/FcGranl to PI-PLC-treated granulocytes.
CD16-granulocytes, which consist mainly of eosinophilsZ6 bound markedly less CSa-F when compared with CD16+ granulocytes ( ... CD16-and CD16' cells could be completely inhibited by anti-C5a MoAb C17/5 (not shown). MNL preparations were investigated in more detail because the expression of C5aR on lymphocyte subpopulations (especially on NK cells) has previously been suggested."-'6 In double-labeling experiments, only CD14' monocytes bound CSa-F. Neither CD3' T lymphocytes, CD20' B lymphocytes, CD16'/ CD56' NK cells, or CDllb' lymphocytes (mainly NK cells and CD8' T lymphocytes) could be stained with CSa-F.
Figure 2 shows one of 10 separate experiments. Binding of C5a-F to MNL was specific because it was inhibitable by an excess of unlabeled C5a or by the neoepitope-specific anti-C5a MoAb C17/5 but not by C3a or a n t i 4 3 MoAb M4/1 (Fig 3) . The NK clone NKC1, which was derived from normal peripheral blood lymphocytes,24 did not bind any CSa-F (not shown). In experiments performed with cells of two different donors, C5a-F reacted with splenic CD14' cells and granulocytes but not with CD3', CDllb', CD16', CD20', or CD56' splenic lymphocytes (not shown).
Response of peripheral blood leukocytes to C5a. Leukocytes were investigated during hemodialysis with cuprophane membranes, which induced the generation of C5a (Fig 4a) . We observed a reduced binding of C5a-F to granulocytes after the start of hemodialysis (Fig 4b) which may reflect the occupancy or, alternatively, the internalization of CSaR-C5a complexes that had been formed in vivo. The transient decrease of granulocytes in peripheral blood during hemodialysis (Fig 4c) may be associated with the increase of the adhesion molecules on granulocytes (Fig 4e) as discussed previously for CR3." Monocytes reacted with transient increases in CR3 as well (Fig 4f) , whereas virtually no changes were detectable on CDllb' lymphocytes (Fig  4d) .
The stimulation of peripheral blood leukocytes in vitro with C5a led to cellular changes that confirmed the binding experiments with C5a-F and the observations made during hemodialysis. Upon C5a stimulation, increases of CR3 and p150,95 (CR4) were detected on myeloid cells but not on lymphocytes (Fig 5) . These increases could be prevented by preincubating C5a with a 100-fold molar excess of anti-C5a MoAb C17/5 (Fab) (not shown). When peripheral blood cells were stimulated with PMA, we observed increases of CR3 and p150,95 not only on myeloid cells but also on lymphocyte subpopulations (Fig 5) . This shows that under the conditions used these lymphocytes are able to respond to adequate stimuli, but not to C5a.
Stimulation of MNL under serum-free conditions with MNL-CM, IFN-y, or in MLCs for 24 to 72 hours did not induce CSaR on lymphocytes (not shown). However, these treatments resulted in a marked reduction of C5aR on monocytes (Fig 6 and 7) , whereas HLA-DR antigens were increased on monocytes under similar conditions (Fig 7) . The reduced binding of CSa-F was also detectable when 1 x lo5 CD14' sorted monocytes (purity >90%) were stimulated with 200 U/mL IFN-y in Iscove's medium. The effect of IFN-y on C5aR
Binding of C5a to stimulated MNL. Table 2) . This suggests that down-modulation of C5aR on monocytes was not due to generation of C5a in cultures stimulated with IFN-y. Moreover, the addition of SO kg/mL of the LPS-binding reagent polymyxin B did not have any effect on IFN-yinduced decreases of CSa-F binding (not shown).
PMA leads rapidly to a decreased binding of CSa-F to granulocytes?8329 We observed a reduced binding of C5a-F to PMA-treated monocytes as well ( Table 3) with defined MoAb reactive with lymphocytic or myeloid cells. CSa-F bound to 10% to 40% of cells in the GRAN window and 10% to 30% of cells in the BLAST window. No binding of C5a-F to cells in the LYMPH gate was detectable. Binding to cells in the BLAST and GRAN windows appeared to be specific because it was saturable at 25 ng CSa-F and inhibitable by preincubation of CSa-F with a 500-fold molar excess of anti-CSa MoAb C17/5 (Fab) (not shown). In double-labeling experiments all C5a-F' cells bound anti-MHC class I MoAb W6131 (not shown). CD34 MoAb My10 bound to cells in the LYMPH window and BLAST window (Fig 8B) as described." However, CD34' cells did not bind any CSa-F (Fig 8B) . All CSa-F-binding cells in the GRAN window expressed high levels of the C D l l b antigen detected by MoAb Leul5-PE (Fig 8C) and the CD15 antigen detected by MoAb MMA (not shown). These antigens are expressed at the promyelocyte stage and increase as the granulocytes mature." FcyRIII (CD16) appears late during neutrophil maturation." CSa-F bound to CD16' granulocytes or granulocyte precursor cells in the bone marrow but also to C D 1 6 cells in the GRAN window (Fig SC) .
CSaR' cells in the blast cell window also expressed high levels of C D l l b (Fig 8C) and CD15 (not shown). The myeloid cell lines U937, THP-I, HL-60, and KG-1 did not bind C5a but incubation of U937 cells with 1 mmol/L db-CAMP for 48 hours induced C5aR as described?* (not shown).
DISCUSSION
Biologically active fluorescein-conjugated C5a was used to evaluate the expression of C5aR on peripheral blood leukocytes and on hematopoietic cells. In previous studies, binding of CSa-F to granulocytes, monocytes, and some lymphocyte subpopulations obtained from normal blood was described."." We were able to reproduce binding of CSa-F to granulocytes and monocytes. Granulocytes consistently demonstrated a narrower distribution in their fluores- cence histograms than did monocytes (Fig 1) as reported previ~usly."~'~ The reason for the broad distribution of C5aR densities on monocytes is not known. Interestingly, CD16-granulocytes, which are probably eosinophils,26 bound much less C5a-F than did CD16' granulocytes ( Table 1) . The binding of C5a-F used in this study appeared to be specific because it was saturable and inhibitable by unlabeled C5a or anti-C5a MoAb (Fig 3) .
In reported chemotaxis experiments, different lymphocyte pop~lations,'~ isolated CD16' lymphocyte^,'^ or enriched large granular lymphocytes16 responded to purified C5a or zymosan-activated serum. Binding of C5a-F was seen with 6 f 3% of peripheral blood lymphocytes," with up to 8% of lymphocyte^,'^ and with CDllb', CD16'
lymphocytes." In this study we did not detect binding of C5a-F to any lymphocyte subpopulation present in peripheral blood (Fig 2) , spleen, or bone marrow (Fig 8) . A recently generated MoAb against the C5a receptor that was obtained as an anti-idiotypic MoAb after immunization with the neoepitope-specific anti-C5a MoAb C17/5 bound to granulocytes and monocytes but not to lymphocytes (Oppermann et al, manuscript in preparation cells of a healthy individual24 did not bind C5a-F. In addition, we did not observe any influence of active purified C5a on the cytotoxicity of MNL against the NK-sensitive cell line K562 in chromium release assays (not shown).
Myeloid cells but not lymphocyte populations were responsive to C5a with respect to increases in the membrane expression of CR3 and p150,95 (Fig 5) . This unresponsiveness of lymphoid cells to C5a is in accord with the failure to detect C5a receptor-specific RNA by northern blots in cells of the lymphoid series." Hemodialysis that led to the generation of C5a (Fig 4a) was accompanied by transient increases of CR3 on granulocytes (Fig 4e) as reported" and monocytes (Fig 4f) , whereas the membrane expression of CR3 on CDllb+ lymphocytes remained stable (Fig 4d) . CR3 and p150,95 are stored in intracellular pools in myeloid cells and translocated to the cell membrane upon short stimulation with C5a or other secretagogue^?^.^^ However, PMA induced increases of CR3 and p150,95 on lymphocyte subpopulations (Fig 5) , indicating the general responsiveness of these cells. The majority of these lymphocytes are CD56' NK cells.37 Recently we have identified (Fig 6 and 7) . The effect of IFN-y was inhibitable by anti-IFN-y but not by anti-C5a MoAb (Table 3) These observations correspond to the findings of Kajita and Hugli;' who observed that mainly nonsegmented neutrophils (band forms) were recruited from bone marrow pools in a rabbit model of CSa-induced neutropenia and subsequent neutrophilia, suggesting that C5a receptors are not expressed on earlier maturation stages of granulocytes. The late-appearing Fc-receptor FcyRIII (CD16)31 was not expressed on all CSa-F-binding granulocytic progenitor cells (Fig 8) . Monocytes probably also express CSaR late during maturation because all cells in the BLAST window expressed high levels of CR3. The suggestion of a late appearence of CSaR during myeloid cell maturation was supported by the absence of CSa-F binding to the immature myeloid cell lines U937, HL-60, KG-1, and THP-1.
